文献速递临床试验与 GCP

利多卡因输注预防乳腺癌术后持续性疼痛(PLAN):多中心随机对照试验研究方案

Prevention of persistent pain with lidocaine infusions in breast cancer surgery (PLAN): study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2024-05-22

PLAN为多中心、平行组、盲法、1:1随机、安慰剂对照试验,纳入1602例乳腺癌手术患者,比较术中静脉输注2%利多卡因(诱导时1.5 mg/kg负荷,继以2.0 mg/kg/h至手术结束)与等体积生理盐水对术后3个月持续性疼痛发生率的影响,并评估疼痛、阿片消耗、情绪躯体功能及成本效果。

要点

  • 术中静脉利多卡因负荷1.5 mg/kg继以2.0 mg/kg/h输注至手术结束,与生理盐水对照。
  • 主要结局为术后3个月持续性疼痛发生率,样本量1602例。
  • 若试验成功,利多卡因输注将整合为乳腺癌管理的标准治疗。

核心结论

  • 该试验旨在为术中静脉利多卡因输注预防乳腺癌术后持续性疼痛提供确定性证据。
  • 若试验成功,利多卡因输注将整合为乳腺癌管理的标准治疗。

研究设计与样本

  • 多中心、平行组、盲法、1:1随机、安慰剂对照试验,纳入1602例拟行肿块切除术或乳房切除术的成人乳腺癌手术患者。
  • 干预组在麻醉诱导时给予2%利多卡因1.5 mg/kg负荷,继以2.0 mg/kg/h输注至手术结束;对照组给予等体积生理盐水。

主要发现

  • 主要结局为术后3个月持续性疼痛发生率。
  • 次要结局包括术后1小时、1-3天及12个月的疼痛发生率和阿片消耗,以及情绪、躯体、功能参数和成本效果。

关键数值与推荐

  • 主要结局指标:术后3个月持续性疼痛发生率。
  • 次要结局指标:术后1小时、1-3天和12个月的疼痛发生率与阿片消耗,以及情绪、躯体、功能参数和成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistent pain is a common yet debilitating complication after breast cancer surgery. Given the pervasive effects of this pain disorder on the patient and healthcare system, post-mastectomy pain syndrome (PMPS) is becoming a larger population health problem, especially as the prognosis and survivorship of breast cancer increases. Interventions that prevent persistent pain after breast surgery are needed to improve the quality of life of breast cancer survivors. An intraoperative intravenous lidocaine infusion has emerged as a potential intervention to decrease the incidence of PMPS. We aim to determine the definitive effects of this intervention in patients undergoing breast cancer surgery. METHODS: PLAN will be a multicenter, parallel-group, blinded, 1:1 randomized, placebo-controlled trial of 1,602 patients undergoing breast cancer surgery. Adult patients scheduled for a lumpectomy or mastectomy will be randomized to receive an intravenous 2% lidocaine bolus of 1.5 mg/kg with induction of anesthesia, followed by a 2.0 mg/kg/h infusion until the end of surgery, or placebo solution (normal saline) at the same volume. The primary outcome will be the incidence of persistent pain at 3 months. Secondary outcomes include the incidence of pain and opioid consumption at 1 h, 1-3 days, and 12 months after surgery, as well as emotional, physical, and functional parameters, and cost-effectiveness. DISCUSSION: This trial aims to provide definitive evidence on an intervention that could potentially prevent persistent pain after breast cancer surgery. If this trial is successful, lidocaine infusion would be integrated as standard of care in breast cancer management. This inexpensive, widely available, and easily administered intervention has the potential to reduce pain and suffering in an already afflicted patient population, decrease the substantial costs of chronic pain management, potentially decrease opioid use, and improve the quality of life in patients. TRIAL REGISTRATION: This trial has been registered on clinicaltrials.gov (NCT04874038, Dr. James Khan. Date of registration: May 5, 2021).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Khan JS, Gilron I, Devereaux PJ, et al. Prevention of persistent pain with lidocaine infusions in breast cancer surgery (PLAN): study protocol for a multicenter randomized controlled trial. Trials. 2024. PMID: 38773653. doi:10.1186/s13063-024-08151-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。